Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil
暂无分享,去创建一个
[1] M. Kukhanova,et al. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 1996, Biochemical pharmacology.
[2] B. Stillman,et al. Cold Spring Harbor Laboratory , 1995, Molecular medicine.
[3] Y. Cheng,et al. Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus , 1995, Antimicrobial agents and chemotherapy.
[4] R. Schinazi,et al. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. , 1995, The Journal of clinical investigation.
[5] J. Colacino,et al. Effect of fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture , 1994, Antimicrobial Agents and Chemotherapy.
[6] R. Schinazi,et al. Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro , 1994, Antimicrobial Agents and Chemotherapy.
[7] R. Schinazi,et al. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro , 1994, Antimicrobial Agents and Chemotherapy.
[8] Y. Cheng,et al. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). , 1994, Journal of medicinal chemistry.
[9] G. Dutschman,et al. Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro , 1994 .
[10] R. Schinazi,et al. Potent Anti‐HIV and Anti‐HBV Activities of (‐)‐L‐β‐Dioxolane‐C and (+)‐L‐β‐Dioxolane‐T and Their Asymmetric Syntheses. , 1993 .
[11] R. Schinazi,et al. Potent anti-HIV and anti-HBV activities of (−)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric syntheses. , 1992 .
[12] V. Skalski,et al. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. , 1992, The Journal of biological chemistry.
[13] R. Schinazi,et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. , 1992, The Journal of biological chemistry.
[14] M. Sachs,et al. Antiretroviral chemotherapy of human immunodeficiency virus infections other than with azidothymidine. , 1992, Archives of internal medicine.
[15] R. Schinazi,et al. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[16] H. Meisel,et al. Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs , 1991, Antimicrobial Agents and Chemotherapy.
[17] H. Mitsuya,et al. Initial Clinical Experience with Dideoxynucleosides as Single Agents and in Combination Therapy , 1990, Annals of the New York Academy of Sciences.
[18] H. Will,et al. Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides , 1990, Antimicrobial Agents and Chemotherapy.
[19] D. Richman,et al. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay , 1990, Antimicrobial Agents and Chemotherapy.
[20] P. Price,et al. Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[21] C. H. Chen,et al. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. , 1989, The Journal of biological chemistry.
[22] J. Hoofnagle,et al. NIH conference. Hepatocellular carcinoma. , 1988, Annals of internal medicine.
[23] G. Acs,et al. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[24] Y. Cheng,et al. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. , 1983, The Journal of biological chemistry.
[25] Lu-Yu Hwang,et al. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.
[26] Y. Cheng,et al. Nucleoside analogues with clinical potential in antivirus chemotherapy. The effect of several thymidine and 2'-deoxycytidine analogue 5'-triphosphates on purified human (alpha, beta) and herpes simplex virus (types 1, 2) DNA polymerases. , 1981, Molecular pharmacology.
[27] W. Rutter,et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.
[28] Y. Cheng,et al. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. , 1994, Biochemical pharmacology.
[29] Progress in the control of viral hepatitis: memorandum from a WHO meeting. , 1988, Bulletin of the World Health Organization.
[30] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.